Castle Biosciences CSTL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $83.68M-3.8% | $87.01M+4.8% | $83.04M-3.6% | $86.19M-2.0% | $87.99M+1.9% | ||
| $20.53M+12.1% | $18.32M-2.1% | $18.7M+6.1% | $17.63M+7.6% | $16.38M+1.2% | ||
| $14.43M+6.8% | $13.52M+4.3% | $12.96M+1.4% | $12.79M+1.6% | $12.59M+6.9% | ||
| $64.9M+14.4% | $56.73M+1.5% | $55.91M-3.7% | $58.07M-0.9% | $58.62M+17.3% | ||
| $2.23M-2.2% | $2.28M0.0% | $2.28M+16.1% | $1.96M-93.1% | $28.33M+553% | ||
| -$18.41M-381% | -$3.83M+43.8% | -$6.8M-60.1% | -$4.25M+84.8% | -$27.93M-790% | ||
| -22%-17.6pp | -4.4%+3.8pp | -8.2%-3.3pp | -4.9%+26.8pp | -31.7%-36.4pp | ||
| $134K+458% | $24K0.0% | $24K+14.3% | $21K+23.5% | $17K-81.5% | ||
| $2.55M-12.1% | $2.9M+2.2% | $2.83M-3.8% | $2.94M-5.0% | $3.1M-8.1% | ||
| -$439K-557% | $96K+100% | $48K— | $0— | $0— | ||
| $2.02M— | —— | —— | —— | -$1.43M-1,127% | ||
| $109K+129% | -$382K-432% | $115K+102% | -$4.67M-1,003% | -$423K— | ||
| -$14.52M-523% | -$2.33M-365% | -$501K-111% | $4.52M+117% | -$25.85M-370% | ||
| -17.4%-14.7pp | -2.7%-2.1pp | -0.6%-5.9pp | 5.2%+34.6pp | -29.4%-40.5pp | ||
| -$0.49-600% | -$0.07-250% | -$0.02-113% | $0.15+117% | -$0.90-381% | ||
| -$0.49-600% | -$0.07-250% | -$0.02-113% | $0.16+118% | -$0.90-357% | ||
| 29.9M+3.1% | 29M-0.3% | 29.1M-1.6% | 29.5M+3.3% | 28.6M-2.2% | ||
| 29.9M+3.1% | 29M-0.3% | 29.1M+0.5% | 28.9M+1.1% | 28.6M+3.0% | ||
| $102.09M+12.4% | $90.84M+1.1% | $89.85M-0.7% | $90.44M-22.0% | $115.92M+40.9% | ||
| -$439K-557% | $96K+100% | $48K— | $0— | $0— | ||
| $83.68M-3.8% | $87.01M+4.8% | $83.04M-3.6% | $86.19M-2.0% | $87.99M+1.9% | ||
| -$18.41M-381% | -$3.83M+43.8% | -$6.8M-60.1% | -$4.25M+84.8% | -$27.93M-790% | ||
| -$14.48M-28,856% | -$50K+98.3% | -$2.99M-257% | -$837K-146% | $1.84M-81.3% | ||
| -$14.48M-28,856% | -$50K+98.3% | -$2.99M-257% | -$837K-146% | $1.84M-81.3% | ||
| -17.3%-17.2pp | -0.1%+3.5pp | -3.6%-2.6pp | -1%-3.1pp | 2.1%-9.3pp | ||
| -$18.41M-381% | -$3.83M+43.8% | -$6.8M-60.1% | -$4.25M+84.8% | -$27.93M-790% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Castle Biosciences's revenue?
- Castle Biosciences (CSTL) generated $339.9M in revenue over the trailing twelve months, down 2.1% year over year.
- Is Castle Biosciences profitable?
- Castle Biosciences is not currently profitable: it reported a net loss of $12.8M over the trailing twelve months, a -3.8% net margin.
- What are Castle Biosciences's profit margins?
- Gross margin is 77.9% and operating margin is -9.8%, with a -3.8% net margin.
- What is Castle Biosciences's earnings per share?
- Castle Biosciences's diluted EPS over the trailing twelve months is $-0.43.
- Where does Castle Biosciences's income statement data come from?
- Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
